2. Immunology/Inflammation
  3. CD28
  4. Lulizumab

Lulizumab  (Synonyms: Humanized Anti-CD28 Recombinant Antibody)

Cat. No.: HY-P99302 Purity: ≥95.0%
COA
SDS
Technical Support

Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is an anti-CD28 domain antibody antagonist. Lulizumab inhibits T-cell activation by selectively targeting the CD28 signal. In a sensitized non-human primate kidney transplantation model, when combined with Carfilzomib (HY-10455), Lulizumab can regulate immune cells and prolong the survival time of the graft.

For research use only. We do not sell to patients.

CAS No. : 2235419-62-0

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Lulizumab Featured Recommendations:

Lulizumab Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is an anti-CD28 domain antibody antagonist. Lulizumab inhibits T-cell activation by selectively targeting the CD28 signal. In a sensitized non-human primate kidney transplantation model, when combined with Carfilzomib (HY-10455), Lulizumab can regulate immune cells and prolong the survival time of the graft[1][2].

Isotype

V-kappa
Species Reactivity

Human
IC50 & Target

CD28
In Vivo

Lulizumab (12.5 mg/kg; subcutaneous injection; once a week; for 4 weeks), when used in combination with Carfilzomib (HY-10455) in a sensitized non-human primate (rhesus macaque) kidney transplantation model, can reduce the level of donor-specific antibodies, regulate immune cells, and prolong the survival time of the graft[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Macaca mulatta were sensitized by performing swapping skin transplants of 3cm diameter patches of dorsal skin between individuals of each pair twice, 8 weeks apart. Then they underwent kidney transplantation[2].
Dosage: 12.5 mg/kg
Administration: Subcutaneous injection; once a week for 4 weeks
Result: Led to a significant reduction in donor-specific antibody levels.
Decreased the number of follicular helper T cells and proliferating B cells in the lymph nodes.
Increased the proportion of naïve CD4 T cells and naïve B cells in circulation, maintained the frequency of regulatory T cells.
Significantly prolonged the median survival time of the grafts.
Caused animals to ultimately experience antibody-mediated rejection and graft failure.
Clinical Trial
Gene ID

940  [NCBI]

Accession
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Molecular Weight

12.01 kDa

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Lulizumab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • V-kappa
Biological Activity
  • Flow cytometric analysis of 106 Jurkat cells with Lulizumab (HY-P99302, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor® 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Cells without incubation with primary antibody were used as the unlabeled control (black).
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Lulizumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Lulizumab2235419-62-0Humanized Anti-CD28 Recombinant AntibodyCD28T cellrhesus macaquekidney transplantation modelInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Lulizumab
Cat. No.:
HY-P99302
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.